NSE
Aarti Pharmalabs LimitedAARTIPHARM
Aarti Pharmalabs Limited is an Indian pharmaceutical company engaged in the manufacturing and distribution of APIs and formulations.
| Key products | APIs, Formulations |
|---|---|
| Geography | India, Export markets including Middle East, Africa, Europe |
| Competitors | Dr Reddy's Laboratories, Cipla, Sun Pharmaceutical Industries |
AI-generated overview — verify before relying on it.
Net institutional flow
+₹88.3 Cr
Institutional buyers
3 in / 2 out
High-impact filings
0 · tilt Neutral
Next corporate action
Interim Dividend - Rs 1.50 Per Share
ex 2026-02-16
Competitive landscape — the read
vs most-traded names| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | AARTIPHARMThis | +₹88.3 Cr | 15 | — | — | — | — |
| 2 | MTNL | +₹41.3 Cr | 331 | — | — | — | — |
| 3 | ATALREAL | +₹7.4 Cr | 363 | — | — | — | — |
| 4 | GATECH | +₹0.4 Cr | 298 | — | — | — | — |
| 5 | IRMENERGY | −₹2.2 Cr | 356 | — | — | — | — |
| 6 | QUADFUTURE | −₹9 Cr | 571 | — | — | — | — |
| 7 | MOBIKWIK | −₹150.9 Cr | 975 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • [object Object]
- • [object Object]
Weaknesses
- • [object Object]
- • [object Object]
Opportunities
- • [object Object]
- • [object Object]
Threats
- • [object Object]
- • [object Object]
AI-generated from our data — verify before relying on it.
Timeline — AARTIPHARM day by day
- 2026-06-12FilingChandrakant Vallabhaji Gogri has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Shareholding Disclosure
- 2026-02-16ActionInterim Dividend - Rs 1.50 Per ShareDividend
- 2025-09-19BulkSELL · ₹42.7 CrBNP PARIBAS FINANCIAL MARKETS
- 2025-09-19BulkBUY · ₹45.1 CrNORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL
- 2025-09-19BulkSELL · ₹55.8 CrSAFECHEM ENTERPRISES PRIVATE LIMITED
- 2025-09-19BulkBUY · ₹48.5 CrVANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VIEIF
- 2025-09-19BulkBUY · ₹52.2 CrVANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND
- 2025-09-15ActionDividend - Rs 2.50 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Scope the deal/action portion with the period chips below.
Filings that matter
- 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Source PDF →
5 deals · 2025-09-19 → 2025-09-19
| Date | Counterparty | Investor type | Side | Value |
|---|---|---|---|---|
| 2025-09-19 | BNP PARIBAS FINANCIAL MARKETS | HNI / other | SELL | ₹42.7 Cr |
| 2025-09-19 | NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL | Institution | BUY | ₹45.1 Cr |
| 2025-09-19 | SAFECHEM ENTERPRISES PRIVATE LIMITED | HNI / other | SELL | ₹55.8 Cr |
| 2025-09-19 | VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VIEIF | Institution | BUY | ₹48.5 Cr |
| 2025-09-19 | VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND | Institution | BUY | ₹52.2 Cr |
5 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
News & chatter on AARTIPHARM
RSS News
0No recent news.
Google News RSS — links open the source.
The Dispatch
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.